Edgewise Therapeutics , Inc., a biotechnology company specializing in pharmaceutical preparations, announced the promotion of ...

BOULDER, Colo. - Edgewise Therapeutics Inc. (NASDAQ:EWTX), a biopharmaceutical company focused on muscle disease treatment ...

Edgewise Therapeutics Inc (EWTX) stock saw a modest uptick, ending the day at $28.3 which represents a slight increase of $1.30 or 4.81% from the prior close of $27. The stock opened at $26.84 and ...

Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) was the target of a significant growth in short interest during ...

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent ...

Paul Matteis, an analyst from Stifel Nicolaus, has initiated a new Hold rating on Edgewise Therapeutics (EWTX).Invest with Confidence: Follow ...

Edgewise Therapeutics Inc. (Nasdaq: EWTX) has promoted Behrad Derakhshan, formerly the Boulder-based muscle disease biopharmaceutical company’s chief business officer, to chief operating officer, and ...

We can readily understand why investors are attracted to unprofitable companies. For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the share ...

- Behrad Derakhshan, Ph.D. promoted to Chief Operating Officer (COO) - Robert Blaustein, M.D., Ph.D., Chief Development Officer, Edgewise Therapeutics (Photo ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...

--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced key changes to its executive team that will strengthen its ...